| Antisense oligonucleotides for the treatment of cardiovascular disease |
2023-5-08 |
2023-6-21 |
|
| Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular … |
2023-5-05 |
2023-6-21 |
|
| Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
2023-4-25 |
2023-6-07 |
|
| Single-stranded rna-editing oligonucleotides |
2023-4-06 |
2023-9-07 |
|
| Antisense oligonucleotides for the treatment of liver disease |
2023-3-27 |
2023-5-10 |
|
| Chemically modified antisense oligonucleotides for use in RNA editing |
2023-3-24 |
2023-5-10 |
|
| Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular … |
2023-2-20 |
2023-4-05 |
|
| Guide oligonucleotides for nucleic acid editing in the treatment of … |
2023-2-13 |
2023-8-17 |
|
| Delivery of oligonucleotides |
2023-1-20 |
2023-3-08 |
|
| Antisense oligonucleotides for the treatment of cardiovascular disease |
2022-12-09 |
2023-1-25 |
|
| Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 … |
2022-12-01 |
2023-1-18 |
|
| Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
2022-11-24 |
2023-1-11 |
|
| Guide oligonucleotides for nucleic acid editing in the treatment of … |
2022-11-14 |
2022-12-28 |
|
| Nucleic acid editing in the treatment of liver disease |
2022-11-11 |
2022-12-28 |
|
| Antisense oligonucleotides for the treatment of bile acid related disorders |
2022-11-11 |
2022-12-28 |
|
| Guide oligonucleotides for nucleic acid editing in the treatment of … |
2022-10-28 |
2022-12-14 |
|
| Heteroduplex rna editing oligonucleotide complexes |
2022-10-21 |
2022-12-07 |
|
| Chemically modified oligonucleotides for adar-mediated RNA editing |
2022-9-30 |
2022-11-16 |
|
| Antisense oligonucleotides for use in the treatment of corneal dystrophies |
2022-3-04 |
2022-11-24 |
|
| Targeted rna editing |
2022-2-24 |
2022-3-17 |
|
| Guide oligonucleotides for nucleic acid editing in the treatment of … |
2022-2-14 |
2022-3-30 |
|
| Use of single-stranded antisense oligonucleotides in prevention or treatment of … |
2022-2-04 |
2022-5-13 |
|
| Ophthalmic compositions comprising viscosifying polymers and nucleic acids |
2021-12-21 |
2022-2-01 |
|
| Antisense rna editing oligonucleotides comprising cytidine analogs |
2021-11-28 |
2022-1-01 |
|
| Antisense oligonucleotides for the treatment of stargardt disease |
2021-10-26 |
2022-5-05 |
|
| Rna editing inhibitors and methods of use |
2021-10-14 |
2021-12-01 |
|
| Antisense oligonucleotides for the treatment of usher syndrome |
2021-9-30 |
2021-10-31 |
|
| Oligonucleotides to treat eye disease |
2021-9-15 |
2021-12-30 |
|
| Chemically modified oligonucleotides for rna editing |
2021-9-14 |
2021-10-31 |
|
| Antisense oligonucleotides for the treatment of cadasil |
2021-8-27 |
2021-10-13 |
|
| Antisense oligonnucleotides for the treatment of cadasil |
2021-8-25 |
2021-10-06 |
|
| Antisense oligonucleotides for rna editing |
2021-7-22 |
2022-1-27 |
|
| Antisense oligonucleotides for nucleic acid editing |
2021-7-19 |
2021-9-30 |
|
| Antisense oligonucleotides for the treatment of leber's congenital amaurosis |
2021-6-27 |
2021-8-31 |
|
| Rna-editing oligonucleotides for the treatment of usher syndrome |
2021-6-24 |
2021-8-31 |
|
| Single-stranded RNA-editing oligonucleotides |
2021-3-26 |
2023-5-16 |
2023-5-16 |
| Antisense oligonucleotides for use in the treatment of usher syndrome |
2021-3-03 |
2023-5-04 |
|
| Antisense oligonucleotides for use in the treatment of usher syndrome |
2021-3-03 |
2022-9-22 |
|
| Guide oligonucleotides for nucleic acid editing in the treatment of … |
2021-2-10 |
2021-3-24 |
|
| Chemically modified single-stranded rna-editing oligonucleotides |
2021-1-20 |
2021-8-05 |
|
| Oligonucleotide therapy for leber congenital amaurosis |
2021-1-08 |
2021-5-13 |
|
| Antisense oligonucleotides for nucleotide deamination in the treatment of … |
2020-12-23 |
2022-11-02 |
|
| Nucleic acid molecules for pseudouridylation |
2020-9-21 |
2020-11-30 |
|
| Delivery of nucleic acids for the treatment of auditory disorders |
2020-6-15 |
2020-12-24 |
|
| Antisense oligonucleotides for immunotherapy |
2020-3-27 |
2020-10-08 |
|
| Antisense oligonucleotides for the treatment of eye disease |
2020-2-07 |
2022-10-25 |
2022-10-25 |
| Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy |
2020-1-17 |
2020-12-24 |
|
| Antisense oligonucleotides for the treatment of stargardt disease |
2019-9-29 |
2019-11-28 |
|
| Antisense oligonucleotides to treat dystrophic epidermoylsis bullosa |
2019-6-17 |
2020-1-23 |
|
| Antisense oligonucleotides for immunotherapy |
2019-6-12 |
2019-7-24 |
|
| Stereospecific linkages in rna editing oligonucleotides |
2019-5-13 |
2021-3-24 |
|
| Antisense oligonucleotides for immunotherapy |
2019-4-02 |
2019-5-15 |
|
| Oligonucleotides for use in the treatment of dystrophic epidermolysis bullosa |
2019-2-28 |
2019-4-17 |
|
| Antisense oligonucleotides for rna editing |
2019-2-11 |
2021-3-18 |
|
| Antisense oligonucleotides for RNA editing |
2018-9-27 |
2018-11-14 |
|
| Antisense oligonucleotides for the treatment of huntington's disease |
2018-8-29 |
2019-3-07 |
|
| Stereospecific linkages in rna editing oligonucleotides |
2018-5-04 |
2018-6-20 |
|
| Antisense oligonucleotides for RNA editing |
2018-2-14 |
2018-3-28 |
|
| Oligonucleotide complexes for use in rna editing |
2018-1-18 |
2018-7-26 |
|
| RNA editing of premature termination stop codons |
2017-12-19 |
2018-1-31 |
|
| RNA editing of premature termination stop codons |
2017-9-25 |
2017-11-08 |
|
| Modified bulgeomers |
2017-5-10 |
2017-6-21 |
|
| Oligonucleotide complexes for use in RNA editing |
2017-5-10 |
2017-6-21 |
|
| Antisense oligonucleotides for enhanced expression of frataxin |
2017-4-26 |
2017-11-02 |
|
| Bulgeomers |
2017-4-20 |
2017-6-07 |
|
| Oligonucleotides for genomic dna editing |
2017-4-12 |
2017-6-29 |
|
| Modified bulgeomers |
2017-2-24 |
2017-4-12 |
|
| Bulgeomers |
2017-2-21 |
2017-4-05 |
|
| Method for increasing the activity of a cystic fibrosis transmembrane … |
2017-2-10 |
2018-6-12 |
2018-6-12 |
| Oligonucleotide complexes for use in RNA editing |
2017-1-19 |
2017-3-08 |
|
| Modified bulgeomers |
2016-12-16 |
2017-2-01 |
|
| Antisense oligonucleotides for use in treating alzheimer's disease |
2016-10-14 |
2019-12-19 |
|
| Modified bulgeomers |
2016-9-27 |
2016-11-09 |
|
| Alzheimer's disease |
2016-9-01 |
2016-10-19 |
|
| Modified Bulgeomers |
2016-9-01 |
2016-10-19 |
|
| Bulgeomers |
2016-8-30 |
2016-10-12 |
|
| Bulgeomers |
2016-6-22 |
2016-8-03 |
|
| Improved treatments using oligonucleotides |
2016-5-09 |
2016-11-17 |
|
| Treatment of genetic diseases |
2016-3-11 |
2016-4-27 |
|
| Targeted rna editing |
2015-12-17 |
2021-8-31 |
|
| Editing |
2015-12-14 |
2016-1-27 |
|
| Treatment |
2015-10-16 |
2015-12-02 |
|
| Treatment of genetic diseases |
2015-10-05 |
2015-11-18 |
|
| Antisense oligonucleotides |
2015-9-17 |
2015-11-04 |
|
| Editing |
2015-7-17 |
2015-8-26 |
|
| Editing |
2015-7-16 |
2015-8-19 |
|
| Antisense oligonucleotides |
2015-5-21 |
2015-7-01 |
|
| Oligonucleotides for making a change in the sequence of a target rna molecule … |
2015-1-12 |
2016-9-28 |
|
| Exon replacement with stabilized artificial rnas |
2013-7-12 |
2014-1-16 |
|